Proudfoot Amanda E I, Power Christine A, Rommel Christian, Wells Timothy N C
Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland.
Semin Immunol. 2003 Feb;15(1):57-65. doi: 10.1016/s1044-5323(02)00128-8.
Chemokines are responsible for specific recruitment of leukocytes that are involved both in homing as well as in inflammation. Dysregulation of the system results in excessive recruitment to inflammatory sites and thus prevention of this recruitment is an effective anti-inflammatory strategy. Chemokine receptors are not limited only to cellular recruitment but are also the essential co-factor along with CD4 that enable HIV-1 viruses to infect cells. In this review we discuss the various points of intervention that can be addressed to provide anti-inflammatory and anti-HIV infectivity therapeutics. These include prevention of the receptor-ligand interaction, prevention of the chemokine-glycosaminoglycan interaction, interfering with the signaling pathways that are induced upon receptor activation, and modification of receptor trafficking pathways. We summarize the status of the approaches that have been undertaken to produce therapeutics that block chemokine action.
趋化因子负责白细胞的特异性募集,这些白细胞参与归巢以及炎症反应。该系统的失调会导致炎症部位过度募集,因此阻止这种募集是一种有效的抗炎策略。趋化因子受体不仅限于细胞募集,而且还是与CD4一起使HIV-1病毒能够感染细胞的必需辅助因子。在这篇综述中,我们讨论了可以采取的各种干预点,以提供抗炎和抗HIV感染性治疗方法。这些包括防止受体-配体相互作用、防止趋化因子-糖胺聚糖相互作用、干扰受体激活后诱导的信号通路以及改变受体运输途径。我们总结了已开展的用于生产阻断趋化因子作用的治疗药物的方法的现状。